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Abstract
The synthetic cannabinoid receptor agonist (SCRA) market is transnational, and the
availability of individual SCRAs changes regularly in response to national and interna-
tional legislative controls. This generates a cyclic pattern and near constant evolution
of SCRA compounds. This study reports toxicology-based and/or seized sample-
based prevalence data relating to SCRA use in prisons from Germany, the United
Kingdom (UK; Scotland and Wales), and the United States (US), representing 4427
individual test results. The study examines SCRA detections in prisons from July
2018 to September 2020, and where possible, prison-based data are compared with
SCRA prevalence data in the wider population. The relative influence of Chinese,
other international, and national drug legislation on the prevalence of individual
SCRAs in prisons is also considered. tert-Leucinate- and valinate-indole- and
indazole-3-carboxamides were the most common SCRA detections, and MDMB-
4en-PINACA was one of the most commonly detected SCRAs in all jurisdictions by
September 2020. However, despite there being a global production and supply
market, there were notable regional differences. Analog controls in German and US
legislation may have led to increased compound diversity that is not reflected in the
UK which has both analog controls and a blanket ban on psychoactive substances.
While there were regional differences, SCRA prevalence in prisons closely aligned
with the SCRAs detected on the local market, demonstrating that SCRA (and possibly
other NPS) monitoring programs in prisons can act as early warning systems for the
wider population in that given jurisdiction.
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1 | INTRODUCTION
Synthetic cannabinoid receptor agonists (SCRAs) are a structurally
diverse group of new psychoactive substances (NPS) that bind to and
activate cannabinoid receptors, CB1 and CB2,
1,2 eliciting a range of
psychoactive and physiological effects. SCRAs have been implicated
in a large number of non-fatal poisonings and drug-related deaths
worldwide.3 Their use and associated harms are of particular concern
in vulnerable populations with high incidence of drug use, including
those in rough-sleeping communities and prisons or correctional
facilities.4
Like other NPS markets, the SCRA market is transnational. Tech-
nological advances, the use of the internet as a global marketplace,
and utilization of international distribution networks have fueled
SCRA production and manufacture, primarily based in commercial
chemical and pharmaceutical operations in China.5 SCRAs available
for purchase on this global marketplace change regularly in response
to changes in legislation. Legislation in producer countries restricts
their production and export, and the implementation of national and
international legislative controls restricts their import and use in other
jurisdictions.2 This generates a cyclic pattern and constant evolution
of new SCRA compounds.
Drug use, and in particular the use of potent NPS, within prison
systems poses organizational challenges, leads to significant harms,
and requires sustained efforts and resources to address. There is a sig-
nificant SCRA market in prisons, with 22 European countries reporting
their use in this context and concerning use in prisons reported in nine
countries including the United Kingdom (UK) and Germany.4 A recent
European Monitoring Centre for Drugs and Drug Addiction
(EMCDDA) report on MDMB-4en-PINACA highlighted seizures of
this recently emerged SCRA from prisons in six European countries.6
As a result of their high potency at the CB1 receptor and their strong
psychoactive effects at low doses,2,7 SCRAs can be infused in active
doses into herbal material, paper, clothing, and other materials which
are then smoked or vaped.4 Impregnation of SCRAs into everyday
materials, particularly paper and card, makes them much more difficult
to detect and allows them to be more effectively supplied to prisoners
through mail systems.
The mode of use (e.g., smoking, vaping, and oral) of SCRAs in
prisons is generally influenced by whether or not smoking bans are in
place. In the United Kingdom, prisons in Wales and Scotland enacted
smoking bans in April 2016 and December 2018, respectively,
although certain approved e-cigarettes are still allowed for personal
use.8–10 In Germany, smoking is allowed in designated areas, such as
in the cell, which is considered a private area.11 In the United States
(US), there are no federal smoking bans for prisons, but many
correctional facilities have enacted smoking bans of varying severity,
including 100% smoke free indoors and 100% smoke free campuses
(indoor and outdoor).12 In the US state of Pennsylvania, where prison
samples reported in this study originated, a tobacco ban was
implemented in July 2019, although the use of non-refillable e-
cigarettes approved by the prison system is permitted in designated
areas.13 The implementation of smoking bans can drive changes in
the mode of use from smoking SCRA-infused herbal blends and
rolled up SCRA-infused papers to vaping the SCRA-infused papers
and other methods of ingestion (e.g., sublingual and in the eye). The
vaping of SCRA-infused papers involves placing small dosage units
(typically 1 cm2) between the heating element and e-liquid cartridge
of an e-cigarette.
In order to limit supply, prison authorities can screen incoming
mail using ion mobility spectrometers (IMS) and other rapid detec-
tion devices,14,15 as well as by use of drug detection dogs.16
Laboratory-based seized sample analysis, particularly when aided by
in-prison screening with rapid detection devices, can help reduce
the supply of drugs in the prisons. Analysis of seized samples also
provides information on the specific compounds in circulation, mix-
tures of compounds being distributed, and the potential concentra-
tions used per dose. The prevalence of SCRAs in correctional
establishments can be monitored by urinalysis from drug testing
programs; however, since SCRAs are extensively metabolized,
and in some cases different SCRAs can produce the same
metabolites,17,18 the exact SCRA compound(s) being used cannot
always be unequivocally identified from urinalysis alone.
Close monitoring of market trends and characteristics is impor-
tant in order to determine the best allocation of resources for dis-
rupting the prison drug market and inform any changes to current
policies and security measures.4,19,20 In addition, accurate data on the
prevalence, use, and effects of the drugs are essential in determining
the effective management of the problems associated with the drugs,
including health risks to individuals using the drugs and the potential
safety and security risks the drugs may pose to other prisoners, prison
staff, and the prison environment as a whole.4,19
This paper reports toxicology-based and/or seized sample-based
prevalence datasets relating to SCRA detections in prisons from four
geographical regions: Germany, the UK (two distinct datasets from
Scotland and Wales), and the United States. The goal was to examine
the transnational evolution of the SCRA market in prisons. Where
possible, prison SCRA prevalence data were compared with available
SCRA prevalence data related to the wider population in the respec-
tive jurisdictions. The relative influence of Chinese, other interna-
tional, and national drug legislation on the prevalence of SCRAs in
prisons in a variety of jurisdictions was considered.
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2 | METHODS
2.1 | Scotland, United Kingdom
The Leverhulme Research Centre for Forensic Science at the Univer-
sity of Dundee works in partnership with the Scottish Prison Service
to analyze non-judicial or non-attributable drug seizures in Scottish
prisons. Prevalence data reported in this study originate from 486 sei-
zures from eight prisons between June 2018 and September 2020. Of
those, 294 had one or more paper and card samples (visually distinct
sets of papers within seizures that are likely of different origin)
positive for SCRAs for a total of 388 positive samples. Many of the
seizures received for laboratory testing were pre-screened using IMS
in situ within the prisons and found to have a positive SCRA indica-
tion. The qualitative and quantitative screening methods used have
been described previously21,22 and involve qualitative analysis by gas-
chromatography-mass spectrometry (GC-MS) and orthogonal confir-
mation by ultra-performance liquid chromatography with photodiode
array and quadrupole time of flight mass spectrometry (UPLC-
PDA-QTOF-MS). Selected results for samples seized between June
2018 and February 2020 have been reported previously.21–23
Additional data from samples seized between October 2019 and
September 2020 are presented herein for the first time.
2.2 | Wales, United Kingdom
The Welsh Emerging Drugs and Identification of Novel Substances
Project (WEDINOS) is a drug testing service in the United Kingdom
operated by Public Health Wales. Prison prevalence data are derived
from the analysis of 1152 seized samples, collected from four prisons
between July 2018 and June 2020. A total of 316 (27.4%) samples
were positive for SCRAs. The prevalence data for the general popula-
tion come from 373 publicly submitted samples found to contain
SCRAs that were received between July 2018 and June 2020. These
publicly submitted sample results are available on the WEDINOS
website.24 Analysis was performed on a Waters Acquity I class
UHPLC with a Water Xevo G2-XS QTOF-MS (Waters, Elstree, UK).
Full details of the analytical method used are provided in Section S1
of the supplementary information.
2.3 | Germany
Prevalence data for 39 German prisons come from the analysis of
2219 urine samples collected between July 2018 and September
2020, of which 745 (33.6%) were positive for SCRAs and SCRA
metabolites. Samples were analyzed using a validated liquid chroma-
tography tandem mass spectrometry (LC-MS/MS) screening method
for SCRA metabolites, regularly updated with all relevant compounds
and previously published in Franz et al.25 Prevalence data for the
German general population market come from two datasets, one from
serum samples and one from infused herbal blends. The serum dataset
comes from the analysis of 2539 serum samples, of which
273 (10.8%) were positive for SCRAs. These samples were collected
between July 2018 and August 2020 for routine analysis. The major-
ity of these samples were submitted by other forensic laboratories in
the context of driving under the influence of drugs offenses. Samples
were analyzed with an LC-MS/MS method regularly updated with all
relevant compounds and previously published in Giorgetti et al.26 The
infused herbal blends dataset comes from the analysis of 468 SCRA-
infused herbal blends, of which 366 (78.2%) were positive for SCRAs.
These samples were purchased online, mainly from shops with
websites in Germany, as part of a market monitoring program. Herbal
blends were analyzed using the method described by Moosmann
et al.27
2.4 | United States
The Center for Forensic Science Research and Education (CFRSE) par-
tnered with the Pennsylvania Department of Corrections to obtain
urine specimens from two prison sites in suburban Philadelphia,
PA. Overall, 570 urine samples were collected between March and
July 2019. Samples were analyzed using a comprehensive, validated
LC-QTOF-MS method described by Krotulski et al.28 A general popu-
lation dataset for SCRA use in the United States was obtained from
NPS Discovery (a program of CFSRE) based on quarterly trend reports
from 2018 Q3 to 2020 Q3.29 These reports use data from forensic
testing of biological fluids, sample extracts, and/or seized drug sam-
ples with analysis by GC–MS and LC-QTOF-MS.
2.5 | Preparation of heat map data visualizations
Heat map data visualizations were created in R (version 3.3.1). The
datasets used to prepare the heat map data visualizations are pro-
vided in the supplementary material (Data S2). An overview of the
method to create the heat map visualizations, including a mark-up of
the R script, is provided in the supplementary material (Data S1). The
R script is provided in the supplementary material (Data S3).
3 | RESULTS AND DISCUSSION
SCRA detections in prisons in Scotland (seizures), Wales (seizures),
and Germany (urinalysis) are depicted as heat maps in Figure 1.
3.1 | United Kingdom (Scotland and Wales)
The SCRAs detected in Scottish and Welsh prisons between 2018 Q3
and 2020 Q3 were almost exclusively tert-leucinate- and valinate-
indole- and indazole-3-carboxamides. In the latest data available for
both jurisdictions, MDMB-4en-PINACA and 4F-MDMB-BINACA
were the most prevalent SCRAs. 4F-MDMB-BINACA was first

















































































































































































































































































































































4 NORMAN ET AL.
detected in 2019 Q1 in Scottish prisons and 2019 Q2 in Welsh
prisons having been first seized in Europe in October 2018.30
Although it had first been detected in Europe as early as 2017,6
MDMB-4en-PINACA was first detected in 2019 Q2 in Scottish
prisons, becoming the most prevalent SCRA by 2019 Q3. In Welsh
prisons, it was first detected in 2019 Q3 and by 2020 Q2 (the last
data available) it was as prevalent as 4F-MDMB-BINACA. Emerging
SCRAs, 5F-EMB-PICA and 4F-MDMB-BICA, were detected for the
first time in Scottish prison seizures in 2020 Q2 having both been first
identified in Europe in materials seized by Belgium customs at the end
of 2020 Q1.31–33
The most notable difference between detections in Scottish and
Welsh prisons was that no detections of 5F-MDMB-PICA had been
reported in Welsh prisons, despite being one of the most prevalent
SCRAs in Scottish prisons over the sampling period. In addition, quin-
olinyl SCRAs, 5F-PB-22 and 5F-APINACA (5F-AKB-48), were
detected in Welsh prisons between 2019 Q1 and 2019 Q4 but were
not detected in Scottish prisons at any point during the study period
(Figure 1). There were also differences in the type of SCRA-infused
materials seized in the prisons between Wales and Scotland. The posi-
tive samples in Scotland were exclusively papers, whereas of the
SCRA-positive samples in Wales, only 9 (2.8%) were paper,
144 (45.6%) were herbal material, 131 (41.5%) were solid materials,
13 (4.1%) were powder, 2 (0.6%) were e-liquids, and the remaining
17 (5.4%) were “not recorded.” This indicates that while the mail
system is a primary smuggling route for SCRAs in Scottish prisons,
other additional smuggling routes are likely utilized in the Welsh
prisons sampled.
In the United Kingdom, SCRAs are controlled as Class B
substances under the Misuse of Drugs Act 1971 (MDA 1971)
(as amended). Under the MDA 1971, drugs are controlled based on
their relative harms into one of three classes, A, B, or C, where Class
A drugs are considered the most harmful. Other Class B drugs include
cannabis, amphetamine, ketamine, and codeine. SCRAs are listed
under structural analog controls which have been adjusted over time
to ensure coverage of newly emerging SCRA classes. Any new SCRAs
not covered by these analog controls are controlled under the Psycho-
active Substances Act 2016 (PSA 2016). This is a blanket ban on the
production and supply of all substances for human consumption with
psychoactive effects, excluding certain exempt substances. Possession
of such substances is not controlled in the general population but is in
custodial establishments, such as prisons.34 All SCRAs detected in
Scottish and Welsh prisons are controlled under the MDA 1971
(as amended). There is no legislative reason to explain why 5F-
MDMB-PICA is prevalent in Scottish prisons but not in Welsh prisons
or why both 5F-PB-22 and 5F-APINACA have continued to be
detected in Welsh prisons despite their earlier control in the United
Kingdom (December 2016, as part of Order 2016 of the Misuse of
Drugs Act 1971),35 China (October 2015),36 and internationally
(November 201837 and March 201738, respectively). These variations
likely reflect differences in local supply networks and/or use of legacy
materials.
Interestingly, as shown in Figure 2, the SCRAs detected in Welsh
prisons mirror SCRA detections in samples submitted by the public to
the WEDINOS drug testing service, 82.84% of which originated from
Wales (15.82% from England and 1.34% from Scotland). Of the pub-
licly submitted samples, 241 (64.6%) were herbal material, 57 (15.3%)
were paper, 55 (14.7%) were e-liquids, 13 (3.5%) were crystalline
materials, 4 (1.1%) were tablets, and 3 (0.8%) were other solid mate-
rials. In publicly forfeited samples, as seen in the prison seizure data,
there were no 5F-MDMB-PICA detections, and 5F-PB-22 and 5F-
APINACA were still being detected up to 2020 Q2. This indicates that
the SCRA prison market is reflective of SCRA prevalence among the
national population. No corresponding general population data are
F IGURE 2 Comparison of synthetic cannabinoid receptor agonists (SCRAs) detected in the Welsh prisons versus the WEDINOS general
population data (>84% samples originating from Wales) using analysis of seized samples
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available for Scotland, but anecdotal information and data from
drug-related death statistics suggest that SCRA use occurs almost
exclusively in prisons in this region.
3.2 | Germany
Metabolites of the tert-leucinate- and valinate-indole- and indazole-
3-carboxamides were the most commonly detected substances in
urine samples collected from German prisoners. By 2020 Q3, as
observed in UK sample seizure data, MDMB-4en-PINACA was the
most commonly detected SCRA, having first been detected in 2019
Q3. 4F-MDMB-BICA was first detected in 2020 Q3, whereas it was
detected in 2020 Q2 in Scottish prisons, and this SCRA may be
increasing in prevalence. It is possible that 5F-EMB-PICA has been
detected in German prisons as early as 2020 Q2 as reported in
Scottish prisons, because the 5F-ABICA amide hydrolysis metabolite,
which is a metabolite of 5F-EMB-PICA, was detected; however, since
it is also a metabolite of 5F-ABICA and 5F-AMB-PICA (MMB-
2201/5F-MMB-PICA), the exact parent SCRA compound could not
be determined solely from the urinalysis. It is notable that the SCRAs
and/or SCRA metabolites detected in German urine samples are con-
siderably more structurally diverse than in the UK seized samples. In
particular, SCRAs incorporating a cumyl head group and/or a
γ-carbolinone core structure are more prevalent in Germany than in
the United Kingdom or the United States and several naphthoylindole
SCRA (e.g., JWH-210) metabolites were detected in urine samples as
recently as 2020 Q3 (Figure 1). The diversity of SCRA detections in
the prison urinalysis reflects the greater diversity in the general
population SCRA market as determined by analysis of seized and test-
purchased materials and serum samples (Figure 3). The greater
diversity observed in the German populations could be due to the
larger sample sizes in the prison urinalysis data and general population
serum data than the other jurisdictions; however, the German
purchased sample dataset shows much the same variation despite a
smaller sample size.
Since the enactment of legislation covering NPS (NpSG = Neue-
psychoaktive-Stoffe-Gesetz) in November 2016, Germany now imple-
ments analog controls for SCRAs as described in detail in previous
publications.39,40 When first enacted, the legislation controlled 86%
of the SCRAs monitored by the European Monitoring Centre for
Drugs and Drug Addiction (EMCCDA), including the most prevalent
SCRAs on the market at that time.39 However, the legislation appears,
at least in its early phases, to have driven SCRA diversity in the
German domestic market with compounds appearing to be specifically
designed to avoid legislative control via the NpSG. These include
SCRAs with a γ-carbolinone core structure (e.g., 5F-Cumyl-
PEGACLONE), azaindoles (e.g., 5F-MDMB-P7AICA), and carbazoles
(e.g., MDMB-CHMCZCA). While these compounds were not preva-
lent within the other jurisdictions in this paper, they have been found
to be prevalent in other jurisdictions outside Germany, such as
Cumyl-CHMEGACLONE which was first reported in Hungary in
December 2018 and showed significant prevalence.41 Legislative
changes to cover SCRAs with increasingly diverse core structures
were enacted via the NpSG in July 2019, and these cover the
γ-carbolinone substances. This may have led to a greater diversifica-
tion of the tail structures producing, for example, the recently
detected Cumyl-CBMICA, an indole-3-carboxamide SCRA with a
cyclobutyl methyl tail.40
3.3 | United States
As far as the authors are aware, there is no formal monitoring or data
collection process in place for monitoring the prevalence and use of
SCRAs in correctional institutions in the United States. The goal of
the sub-study was to test prison populations to determine the extent
of SCRA use in a single geographical location within the United States.
Of the 570 urine samples tested, 14 samples (2.4%) were positive for
SCRA metabolites: 11 (1.9%) were positive for 5F-MDMB-PICA
3,3-dimethylbutanoic acid and 3 (0.5%) for 4F-MDMB-BINACA
3,3-dimethylbutanoic acid. Drug positivity rates reported by the Penn-
sylvania Department of Corrections between October 2018 and
September 2019 ranged between 0.3% and 0.9%.42 The increase in
positivity among those testing positive for SCRAs could be explained
by the use of a comprehensive testing methodology and a regularly
updated library database (i.e., testing for more appropriate drugs
based on current and emerging trends). For example, 4F-MDMB-
BINACA was the newest SCRA to emerge around the time of testing
and incorporation of this analyte into the database yielded positive
results that would otherwise be missed without vigorous and novel
protocols.
Within the US general population SCRA market, as shown in
Figure 4 based on the data from NPS Discovery trend reports,29 4F-
MDMB-BINACA was first detected in December 2018.43 Quickly, 4F-
MDMB-BINACA became the second most prevalent SCRA in the
United States behind 5F-MDMB-PICA in 2019 Q1. Data show that
4F-MDMB-BINACA began having widespread implications among
forensic toxicology casework, including medicolegal death investiga-
tions, often in combination with 5F-MDMB-PICA early on.44 Interest-
ingly, in the prison population study, the metabolite of 4F-MDMB-
BINACA was detected in urine samples as early as March 2019. This
suggests that the drug markets leading to overdose deaths at least
overlap with the drug markets fueling SCRA use in prisons and also
shows the quick emergence of new SCRAs within the prison system
just a short time (or immediately) after their emergence in the general
population.
The US general population data from NPS Discovery demonstrate
similar trends and emergence timelines as the National Forensic Labo-
ratory Information System (NFLIS, a program of the Drug Enforce-
ment Administration) data.45 A heat map comparison of the two
datasets can be found in Figure S3.1 of the supplementary informa-
tion. NFLIS data come from the analysis of seized drug samples by
federal, state, and local laboratories throughout the United States, in
comparison to NPS Discovery, which in addition utilizes biological
fluids analysis data. The emergence of new SCRAs appears to be




























































































































































































































































































































































































































































































































































































8 NORMAN ET AL.
similar between NPS Discovery and NFLIS; although since NFLIS typi-
cally only report their SCRA detections in mid-year and annual
reports, the first emergence of a SCRA compound can be more diffi-
cult to determine using this dataset. 4F-MDMB-BINACA was first
detected in the 2018 annual report, not the mid-year report, indicat-
ing that NFLIS also had first detections of 4F-MDMB-BINACA in
2018 Q3 or Q4. On the other hand, they reported detections of
MDMB-4en-PINACA in the 2019 mid-year report, indicating detec-
tions in 2019 Q1 or Q2, whereas NPS Discovery had first detections
in 2019 Q3. In addition, NPS Discovery seems to have more variation
in their SCRA detections than NFLIS; however, NFLIS do not report
the exhaustive list of SCRAs detected but include an “other synthetic
cannabinoids” category that constitutes between 16.63% and 19.77%
of SCRA detections.
The United States uses both individual drug scheduling actions
and analog controls for SCRAs through the temporary or permanent
scheduling of compounds plus their isomers under Schedule I of the
Controlled Substances Act (CSA).46 The definition of an isomer, both
optical and positional, is provided in Title 21 of the Code of Federal
Regulations (CFR).47 5F-MDMB-PICA was temporarily scheduled on
28 December 2018,48 the same month that 4F-MDMB-BINACA was
first detected in the general population samples. 4F-MDMB-BINACA
is treated as a “positional isomer” of 5F-AMB-PINACA (5F-AMB; 5F-
MMB-PINACA), which was scheduled on 10 April 2017,49 and there-
fore does not require separate scheduling action. It is unknown
whether this was obvious to SCRA producers who may have been try-
ing to circumvent US legislation.
3.4 | Legislative changes as a driver of SCRA
prison market diversification
International and national legislation is clearly a significant driver for
diversification of the SCRAs detected in prisons (and SCRA availability
in the general population) at both local and global levels. Such legisla-
tive changes can be classified as (i) national actions in producer/
exporter jurisdictions directly affecting availability on the global SCRA
market; (ii) changes made to international legislation via the World
Health Organization (WHO) Expert Committee on Drugs and Drug
Dependence (ECDD), which often highlights drugs to be considered
for control up to a year in advance as part of a critical review process;
and (iii) national legislation in jurisdictions into which SCRAs are impo-
rted and consumed (e.g., MDA 1971 in the United Kingdom, NpSG in
Germany, and CSA in the United States).
Legislation controlling SCRA production and export in SCRA-
producing countries, such as China, seems to have the greatest influ-
ence on the availability of compounds worldwide.50 When new
SCRAs emerge in response to legislative changes in China, they tend
to do so in a global manner and previously prevalent substances tend
to leave the market relatively quickly. For example, it was determined
that the August 2018 ban of eight SCRAs by China, including the two
most prevalent SCRAs at the time, AMB-FUBINACA (AMB-FUB,
FUB-AMB), and 5F-MDMB-PINACA (5F-ADB), resulted in these
SCRAs rapidly disappearing from illicit markets in Scotland, Germany,
and New Zealand,21,39,51 as well as Wales (Figure 2) and the United
States (Figure 4) as shown herein by the data presented. 5F-MDMB-
PICA appeared on the market soon after. 5F-MDMB-PICA had origi-
nally been detected in 2016 but had disappeared from the market in
2017.52 Its re-emergence was reported in the German prison and
serum general population datasets (Figure 3) and in the United States
in 2018 Q3 (Figure 4) and in Scottish prisons in 2018 Q4 (Figure 1).
This was followed by 4F-MDMB-BINACA, with first reports in Europe
and the United States in 2018 Q4 (October30 and December, respec-
tively). 4F-MDMB-BINACA was then detected in Scottish and
German prisons in 2019 Q1 and Welsh prisons in 2019 Q2. The
emergence of 4F-MDMB-BINACA may have been in response to the
temporary scheduling of 5F-MDMB-PICA in the United States in
December 2018, which demonstrates that local legislative changes
may perhaps, on occasion, have an effect at a global level, although no
causal link has been established.
In October 2019, the WHO ECDD indicated that 5F-MDMB-
PICA and 4F-MDMB-BINACA were under review for consideration
for international control with the legislation coming into force on
3 November 2020.6,53 The increasing prevalence of MDMB-4en-
PINACA in the United Kingdom, Germany, and the United States
from 2019 Q2 onwards may have been a pre-emptive response to
this, although MDMB-4en-PINACA was detected in Europe as
early as 2017.54,55 MDMB-4en-PINACA is now the most com-
monly detected SCRA in Scottish prisons and in Germany as a
whole and is the second most prevalent SCRA detected in the
United States and Wales as of 2020 Q2. Recently reported data
from 2020 Q4 from NPS Discovery show that MDMB-4en-
PINACA is now the most commonly detected SCRA in the
United States.56 MDMB-4en-PINACA is now being considered
forinternational control at both the European and global level by
EMCDDA and WHO ECDD, respectively.6,54 If recommended for
control at a global level by WHO ECDD, the control may not
come into force until November 2021. The emergence of 4F-
MDMB-BICA and 5F-EMB-PICA on the drug market in 2020 Q2
may therefore again be a pre-emptive market response to the con-
trol of 5F-MDMB-PICA and 4F-MDMB-BINACA and also, possibly,
to the future international control of MDMB-4en-PINACA.
While the emergence of prevalent SCRAs is very similar across all
jurisdictions, being influenced by legislation in producer countries and
international controls, national legislation can also drive increased
diversity in local markets as well as international markets. There is rel-
atively little diversity in the SCRA market in prisons in the United
Kingdom with a limited number of compounds being detected at any
given time, all with similarly high potency and efficacy, where pharma-
cological information is available.23,57 Since the current UK legislation
covers the most prevalent SCRAs on the market under analog controls
(MDA 1971) and all other SCRAs that may not be covered under the
PSA 2016, the United Kingdom may no longer be a driver of market
diversification at a local or international level. In contrast, the analog
controls in Germany (NpSG) and the United States (CSA) appear to
have led to increased diversity in the local market that does not
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appear to be reflected in other jurisdictions (i.e., γ-carbolinone SCRAs
are rarely seen in the United Kingdom and United States).
There are some interesting regional differences that cannot be
explained by legislation. For example, WEDINOS has never detected
5F-MDMB-PICA despite it being one of the most commonly detected
SCRAs in the other jurisdictions and worldwide for, in some places,
more than a year. This demonstrates that market evolution is complex
and while legislation can be an important driver for SCRA market
change, there are other variables that can influence the availability of
a specific compound in a particular jurisdiction (e.g., trafficking routes,
local supply networks, user interest/reports, and adverse effects).
4 | CONCLUSION
SCRAs detected in prisons closely align with the SCRAs detected on
the local market, but there are regional differences despite a global
market for production and supply. This finding is significant and criti-
cally important for combating the emergence and proliferation of
SCRAs in the future. This transnational study demonstrates that SCRA
(and possibly other NPS) monitoring programs in prisons can act as
early warning systems for the wider population in that given jurisdic-
tion. Such monitoring programs should, where possible, be near real-
time and should inform the application of detection methodologies
designed to limit SCRA supply into prisons to ensure their effective-
ness and ability to reduce harm. Where urinalysis is deployed for the
testing of urine samples collected from prison populations and where
targeted detection methods are employed, it is imperative that those
methods are kept up to date with relevant testing panels by incorpo-
rating new SCRAs reported nationally and internationally. A laboratory
must constantly monitor changing drug trends, especially for NPS and
particularly for SCRAs, and incorporate new drugs into testing meth-
odologies as rapidly as possible; otherwise, positive results within the
population could be missed and drug use could be wrongly counted or
categorized.
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